Compare TCPC & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | TMCI |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 279.6M |
| IPO Year | 2006 | 2021 |
| Metric | TCPC | TMCI |
|---|---|---|
| Price | $4.00 | $4.53 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 6 |
| Target Price | $3.50 | ★ $4.77 |
| AVG Volume (30 Days) | ★ 632.9K | 221.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 18.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $3.08 | $1.17 |
| 52 Week High | $6.79 | $7.42 |
| Indicator | TCPC | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 49.78 |
| Support Level | $3.67 | $4.25 |
| Resistance Level | $3.98 | $4.86 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 15.96 | 41.38 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.